A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies (NCT07195916)

🧪 Interventions in This Study

• INCA036873 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (22 Sites)

• City of Hope Medical Center — Duarte, California
• University of California San Diego Medical Center, Moores Cancer Center — La Jolla, California
• University of Michigan — Ann Arbor, Michigan
• The University of Nebraska Medical Center — Omaha, Nebraska
• Memorial Sloan Kettering Cancer Center — New York, New York
• Scri Oncology Partners — Nashville, Tennessee
• Vanderbilt Medical Center — Nashville, Tennessee
• Md Anderson Cancer Center — Houston, Texas
• Macquarie University Hospital — Sydney, New South Wales
• Princess Alexandra Hospital Australia — Woolloongabba, Queensland
• Cancer Research Sa — Adelaide, South Australia
• Peter Maccallum Cancer Centre-Royal Melbourne Hospital — Melbourne, Victoria
• Cliniques Universitaires Ucl Saint-Luc — Brussels,
• Universitair Ziekenhuis Antwerpen — Edegem,
• Universitair Ziekenhuis Gent (Uz Gent) — Ghent,
• Universitair Ziekenhuis Leuven — Leuven,
• Aarhus University Hospital — Aarhus,
• Rigshospitalet Uni of Hospital of Copenhagen — Copenhagen,
• Aou Policlinico S. Orsola-Malpighi — Bologna,
• Fondazione Irccs Istituto Nazionale Dei Tumori — Milan,
• Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore — Rome,
• Centro Ricerche Cliniche Di Verona — Verona,

📞 Contact the Study Coordinator

Phone: (855) 463-3463

Email: medinfo@incyte.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumors

• Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
• A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
• Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
• Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona

Explore by condition: All Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.